Andrew Cooper

Anthony Petrone

Marie Thibault

Craig Bijou

Michael Matson

Michael Petusky

Rohin Patel

David Turkaly

Joanne Wuensch

Lawrence Solow

Anthony Occhiogrosso

David Rescott

Kristen Stewart

Larry Solow

Mike Matson

- Mauna Kea Technologies reported **Q3 2025 total revenue of €1,935K**, representing a **+16% increase at constant exchange rates** compared to Q3 2024.  **[313143_db50a3b506974fb2a908a6eaf780f758_0]** 
- **U.S. sales surged +31% at constant exchange rates** in Q3 2025, marking continuous acceleration and accounting for over **75% of the Group's product sales** (excluding licenses).  **[313143_db50a3b506974fb2a908a6eaf780f758_0]** **[313143_db50a3b506974fb2a908a6eaf780f758_1]**  U.S. system sales also **doubled** year-to-date compared to the same period in 2024.  **[313143_db50a3b506974fb2a908a6eaf780f758_0]** **[313143_db50a3b506974fb2a908a6eaf780f758_1]** 
- The company's cash runway extends to the **end of November 2025**, and it is pursuing a safeguard plan, estimating a need for **€5 million until the end of 2026** and **€8 million to achieve profitability in 2027**.  **[313143_db50a3b506974fb2a908a6eaf780f758_1]**  A hearing for the safeguard plan is scheduled for **October 27, 2025**.  **[313143_db50a3b506974fb2a908a6eaf780f758_2]** 
- Revenue from Asia was **zero** in Q3 2025 due to issues with the joint venture in China, while EMEA & RoW business activity grew by **+18% at constant exchange rates**.  **[313143_db50a3b506974fb2a908a6eaf780f758_0]** **[313143_db50a3b506974fb2a908a6eaf780f758_1]**

Mauna Kea Technologies Announces Q3 2025 Revenue and Financial Update

- **Astria Therapeutics** has commenced patient recruitment in the European Union (EU) for its **Phase III ALPHA-ORBIT trial** of **navenibart**.  **[313143_c5dc308829a543df8a01df06a3fd0817_0]** 
- Navenibart is an investigational plasma kallikrein inhibitor monoclonal antibody being developed for the treatment of **hereditary angioedema (HAE)**, with potential dosing every **three or six months**.  **[313143_c5dc308829a543df8a01df06a3fd0817_0]** **[313143_c5dc308829a543df8a01df06a3fd0817_1]** 
- The trial, authorized by the European Medicines Agency (EMA), has activated **32 sites across ten EU countries** and aims to evaluate the efficacy and safety of navenibart in up to **135 adults and 10 adolescents** with HAE Type 1 or Type 2.  **[313143_c5dc308829a543df8a01df06a3fd0817_0]** **[313143_c5dc308829a543df8a01df06a3fd0817_1]**

Astria Therapeutics Initiates EU Patient Recruitment for ALPHA-ORBIT Phase III Trial

HAEMONETICS (HAE)